chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a consumer concerning her 16 year old daughter with tachycardia and sulfa allergy who on 09-AUG-2007, 15-OCT-2007, 26-MAR-2008 and 02-JUL-2009 was vaccinated with the first, second, third and fourth dose of GARDASIL (lot # not reported). There was no concomitant medication. On 16-JUL-2009, two weeks after the fourth dose of GARDASIL, the patient experienced a fast heart rate and severe acne. The patient sought medical attention via office visit. There were no laboratory diagnostics studies performed. At the end of October 2009, the patient had recovered. Additional information has been requested.
My eye started to swell and turn red/ both eyes were swollen, painful, and red; My eye started to swell and turn red/ both eyes were swollen, painful, and red; My eye started to swell and turn red/ both eyes were swollen, painful, and red; This is a spontaneous report from a contactable consumer (patient) reported for herself. A 38-years-old female patient (patient was not pregnant at the time of vaccination) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EW0158, Expiration date: unknown) via an unspecified route of administration, administered in left arm on 16Jul2021 at 15:00 pm (age at vaccination was 38 years) as dose 2, single for COVID-19 immunization. The patient's medical history included hypoglycemia and uveitis. The patient had known allergy to walnuts. Concomitant medication or other medication the patient received in two weeks included Plexus supplements. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EW0158, Expiration date: unknown) via an unspecified route of administration, administered in right arm on 25Jun2021 at 16:45 pm (age at vaccination was 38 years) as dose 1, single for COVID-19 immunization and the patient's eyes were swollen, painful and red after the first dose of vaccine. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 17Jul2021 at 21:15 pm, the day after her shot towards bedtime, the patient's eye started to swell and turn red. When she woke up in the morning the second day, both eyes were swollen, painful and red. Since that happened with the first dose, she did not call her doctor. The patient was using the same eye drops as prescribed before for the events. The outcome of the events was resolving.   Follow-up attempts are completed. No further information is expected.
Up to date with covid vaccination yet admitted to hospital with symptomatic covid infection PCR + 5/21/22
Immediate headache, severe pain in shoulder and base of head numbness, burning, tingling. Went to Medical Dr. She Said they hit a nerve. 4 days later was in the ER. Still having Severe pain numbness and burning and headache
Dose 1: Flu like symptoms within 24 hrs lasting 4 days. Extreme fatigue, fever, nausea, vomiting, diarrhea, migraine headaches lasting 2-3 days at a time for 2 weeks post vaccination. Body aches, chills.  Dose 2: worse flu like symptoms starting 8-10 hours after second injection. Chills, fever, chattering teeth uncontrollably, vomiting, nausea, severe muscle and joint pain without relief using OTC ibuprofen and Tylenol or Rx tramadol. Fatigue since first vaccine worsened after serving and has continued without relief. I?ve had severe migraine headaches lasting 2-3 days at a time, with only 1-3 days between them since 2nd dose that are worsening and that do not go away with standard otc headache medication (ibuprofen, Tylenol), or Rx Tramadol. My fatigue is not lessening. I am staying hydrated and it has no effect on these lingering symptoms.
Mast cell activation disorder. Increasing allergy, intolerance, and anaphylactoid reactions to foods and drugs.  Tachycardia, cognitive impairment, vertigo, loss of vision, headache, edema, weight loss, hyperglycemia, itching.
40 minutes after she had a bad reaction/ other reactions; Cannot do physical labor; muscle aches; She could only work 3 hours a day because one of the symptom is extreme tiredness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (40 minutes after she had a bad reaction/ other reactions), GENERAL PHYSICAL HEALTH DETERIORATION (Cannot do physical labor), MYALGIA (muscle aches) and FATIGUE (She could only work 3 hours a day because one of the symptom is extreme tiredness) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (40 minutes after she had a bad reaction/ other reactions). an unknown date, the patient experienced GENERAL PHYSICAL HEALTH DETERIORATION (Cannot do physical labor), MYALGIA (muscle aches) and FATIGUE (She could only work 3 hours a day because one of the symptom is extreme tiredness). At the time of the report, VACCINATION COMPLICATION (40 minutes after she had a bad reaction/ other reactions), GENERAL PHYSICAL HEALTH DETERIORATION (Cannot do physical labor), MYALGIA (muscle aches) and FATIGUE (She could only work 3 hours a day because one of the symptom is extreme tiredness) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.  Reporter stated that patient only took one shot of Moderna two years ago (exact date is unknown) and had other reactions and its been two years. Patient went to 19 doctors and no one could help her.
Jynneos vaccine squirted out during the administration to the patient and a substantial amount came out; Case reference number US-BN-2023-001122 is a spontaneous case report initially received from a pharmacist via Communication (reference number: USBAV23-0842) on 28-Jun-2023 and concerns a 67-year-old male patient.  The patient's relevant medical history and concomitant medication details were not provided.  On an unspecified date, the patient was vaccinated with the first dose of Jynneos (batch number: unknown) at an unknown dose, route or site of administration, for monkeypox prophylaxis.  On an 28-Jun-2023, an unknown amount of time after the first dose, the patient was vaccinated with a second dose of Jynneos (batch number: FDP00015) at initial dosage of 0.5 miliiters that squirted out during the administration and a substantial amount came out, administered subcutaneously in the back of the arm (explicitly coded as 'vaccine underdose'). As reported, new syringe was used and the issue was reported as resolved (to be confirmed).  As reported, gloves were used during the administration and the pharmacist had no contact with the product but was wondering if the patient needs to be revaccinated.  At the time of the initial report, it was unknown if the patient experienced any adverse event due to Jynneos vaccination.  Additional information received from on 29-Jun-2023 included local case ID.  Additional information received from on 07-Jul 2023: New information included confirmation that did not supply the syringe in question and no PQC should be captured and information about revaccination with a new syringe that was potentially done to be confirmed.; Reporter's Comments: A 67-year-old male patient was vaccinated with a second dose of Jynneos, at initial dosage of 0.5 miliiters that squirted out during the administration and a substantial amount came out, administered subcutaneously in the back of the arm, which is considered as vaccine underdose. It was unknown if the patient experienced any adverse event due to Jynneos vaccination. Underdose is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Underdose has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 67-year-old male patient was vaccinated with a second dose of Jynneos, at initial dosage of 0.5 miliiters that squirted out during the administration and a substantial amount came out, administered subcutaneously in the back of the arm, which is considered as vaccine underdose. It was unknown if the patient experienced any adverse event due to Jynneos vaccination. Underdose is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Underdose has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
This case was reported by a nurse via sales rep and described the occurrence of vaccination failure in a elderly patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown. It was unknown if the reporter considered the vaccination failure and shingles to be related to SHINGRIX. Additional details were provided as follows: This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization for SHINGRIX, time to onset for event shingles were not provided. The age at vaccination was not reported. The patient was over the age of 70 years of age at the time of reporting. The patient received a SHINGRIX vaccine and broke out with shingles. This was all the information that the patient has provided. The healthcare professional explained that she needed to report the adverse event and said that she would not release any information without speaking to the patient first. The healthcare professional also instructed the patient to contact GlaxoSmithKline to report the adverse event.
I went home and took a nap. When I woke up, I had dizziness. I also had shortness of breath that would become apparent when doing any activity such as switching out the laundry. I also had anxiety and palpitations. Most symptoms later 2-3 weeks. However, the dizziness stayed. It became a little better over time but was not linear improvement. I was unable to drive for about 10 weeks. After the 10 weeks, I was still mildly dizzy with more intense dizziness returning for about a week every 3 weeks. I still had an  episode of intense dizziness 5 months after vaccination, lasting 1 week. It is now 6 months after vaccination and I generally feel more prone to dizziness. I have been drinking 60-80oz water per day and taking magnesium, vitamins D, C, Zinc, B-complex, and Tumeric. I notice dizziness returns when I fail to keep up with water intake and  vitamins.  I also feel traumatized my the experience.
Varicella vaccine administered on 3/28/11. On 3/29/11 evening, patient noted localized redness and swelling at injection site. On 3/30/11, I confirmed mild redness, and swelling to injection site left arm measuring 5.5 cm x 3 cm. Mild tenderness to touch. 4-1-11 - Redness, swelling, tenderness resolved.
Information has been received from a registered nurse concerning an 8 year old white female student who on 13-May-1996 was vaccinated subcutaneously with a first dose of varicella virus vaccine live (lot #612223/1129B). On 17-Nov-2003 the patient "contracted" varicella. Subsequently, the patient recovered. No further information is expected.
Fever X 2 days, skin lesions 10-12+ X 1 day with erythema; no vesicles. (+) pruritus all over body.
Hot flashes; Sore throat; Nasal drip; Difficulty concentrating; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Jul2021 at 16:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to the vaccination, the patient was diagnosed with COVID-19). The patient had no known allergies. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN), sertraline (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN), all for unknown indications from unknown date and unknown if ongoing. The patient did not receive any other vaccine within 4 weeks prior to the COVID-19 vaccine. On 19Jul2021 at 23:15, the patient experienced hot flashes, sore throat, nasal drip and difficulty concentrating. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events experienced hot flashes, sore throat, nasal drip and difficulty concentrating was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Client presented to outreach clinic for COVID vaccine on 9/14/21. Client did not have a COVID Vaccine Card and requested the Pfizer vaccine.  Reports it was his first shot. This writer was unable to look up client's vaccine record as our computer system was down. Pfizer vaccine 0.3mL was administered to left deltoid at 1435 on 9/14/21 and later entered into WebIZ.  On 11/10/21, the client presented to the  County Health Department for a "second dose of Pfizer". It was then discovered, when looking at his vaccine record, that he received a dose on Moderna COVID vaccine on 3/30/2021 at another COVID vaccine outreach.  A second dose of Pfizer COVID vaccine was not administered on 11/10/21.  Client denies any adverse affects.
Red rash  surrounding injection site. Rash is about 4 inches by 6 inches
Since getting the second dose, my periods have been essentially nonexistent when they use to be super regular, now I'll randomly have a blood clot fall out; Since getting the second dose, my periods have been essentially nonexistent when they use to be super regular, now I'll randomly have a blood clot fall out; Nerve pain in both arms; This is a spontaneous report from a contactable other hcp. A 24-years-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: Not reported) via an unspecified route of administration, right arm on 02Apr2021 (at the age of 24-years-old) as single dose for COVID-19 immunisation. The patient was not pregnant at the time of vaccination. The patient's medical history included allergies to Latex from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient did not receive any vaccines within 4 weeks prior to the covid vaccine. Prior to vaccination, the patient was not with diagnosed with COVID-19. Since the vaccination, the patient was not with diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: Not reported) via an unspecified route of administration, in left arm on 12Mar2021 (at the age of 24-years-old) as single dose for COVID-19 immunisation. It was reported that since getting the second dose on 22Apr2021 the patient's periods had been essentially non-existent when they use to be super regular, now patient randomly have a blood clot fall out. The patient also been experiencing nerve pain in both arms. The patient did not receive any treatment for the events. The patient was not recovered from the events.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal relationship between the event Blood clot and suspect drug BNT162B2 cannot be excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
High fever 101.7 for two days.  Extreme shakes all night on the25th.  Advil taken every four hours.   Stomach cramps and loose bowels the next day.
A few minutes after patient was vaccinated, patient stated that he felt dizzy and lightheaded. Patient's vitals were taken and BP was 79/60, RR 18, Temp 99.4, HR 60. Patient was given water and turned a fan on and placed it close to the patient.  Vitals were taken again 15 minutes later and were stable. BP 111/81, HR 70, Temp 98.6, RR 18. Patient was monitored for a total of 45 minutes. Patient was stable before allowed to leave.
ROUND DIMED SIZED YELLOWISH (LEGAL PAD COLOR) AT THE INJECTION SITE SPOT THEN INSIDE OF SPOT A BLACK SPOT; RIGHT ARM STARTED ACHING ON TOP OF SHOULDER AND FELT LOOSE; VERY LITE YELLOW SPOT THE SIZE OF AN ERASER HEAD WITH 1 RED SPOT/2 RED SPOTS LIKE A TRIANGLE; PIN PRICK AT INJECTION SITE; This spontaneous report received from a patient concerned a 77 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, expiry: 21-SEP-2021) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 11-APR-2021, the patient experienced pin prick at injection site. On 18-AUG-2021, the patient experienced very lite yellow spot the size of an eraser head with 1 red spot/2 red spots like a triangle. On an unspecified date, the patient experienced round dimed sized yellowish (legal pad color) at the injection site spot then inside of spot a black spot, and right arm started aching on top of shoulder and felt loose. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from pin prick at injection site on 11-APR-2021, was recovering from round dimed sized yellowish (legal pad color) at the injection site spot then inside of spot a black spot, had not recovered from very lite yellow spot the size of an eraser head with 1 red spot/2 red spots like a triangle, and the outcome of right arm started aching on top of shoulder and felt loose was not reported. This report was non-serious.
Called 911, hospital dianosed with Vertigo.   woke up in bed during night turned to right side and got dissy and nausus, happened twice called 911, hispital dianosed with vertigo , ct scan showed no clots in neck or brain,  said could be iner ear, follow up with family doctor. was givenMeclizine 25 mg tablets,  Ondansetron ODT   4mg tablets
A vial with expired vaccine was diluted with 1.8 ml normal saline and administered to patient.
pt recvd vax 5MAY93; 6MAY94 had acute exacerbation of known asthma requiring Pred;
Redness, excessive swelling from shoulder to elbow in injected arm, hot and painful to touch, resolved after 3-4 days, monitored, used TYLENOL.
Patient developed redness, spreading gradually over the course of 6 days following injection. Symptoms began the evening of receiving and demonstrates a pruritic 10 cm x 20 cm red/erythematous rash.
My tongue swelled and felt like it was scorched with boiling water, difficult to swallow and breathe properly. I took benadryl which help the reaction stay steady. The reaction lasted about 24 hours.
Information has been received from a physician concerning a 5 year old patient with no medical history who on 10-MAY-2007 was vaccinated with 0.5 ml dose of ProQuad (Lot # 657297/0429U). There were no concomitant medication. On approximately 10-MAY-2007 the patient experienced fever, vomiting and rash. It was reported that the patient had symptoms the night after vaccination and was seen in the office the next day on approximately 11-MAY-2007. At the time of report, the patient was not recovered. No diagnostic laboratory procedures were undertaken. A product quality complaint was not involved. Additional information will be provided if available. This is one of several reports received from the same source.
i was sick with flu like symptoms; i was sick with flu like symptoms; chills; hot; cold flashes; achy; i am extremely tired; This is a spontaneous report from a contactable consumer (reported for himself).  This 47-year-old male patient received second dose of BNT162B2 (Pfizer covid-19 vaccine, solution for injection, Batch/Lot number: EP6955) via an unspecified route of administration at left Arm on 17Apr2021 09:00, as a single dose for covid-19 immunization. The patient did not have any medical history or allergy to medications, food or other products. Concomitant medications were not reported. He received first dose of BNT162B2 (Pfizer covid-19 vaccine, solution for injection, Batch/Lot number: EP6955) via an unspecified route of administration at left Arm on 27Mar2021 09:00, as a single dose for covid-19 immunization. On 18Apr2021 07:00, he was sick with flu like symptoms, chills, hot, cold flashes, achy and felt extremely tired. He did not receive any treatment events. He did not visit doctor or other healthcare professional office/clinic or emergency room/department or urgent care. He did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was recovering from the events of sick with flu like symptoms, chills, hot, cold flashes, achy and felt extremely tired. He was not diagnosed with COVID-19 prior to vaccination and was not tested for COVID-19 since the vaccination.   No follow-up attempts are needed. No further information is expected.
This spontaneous report was received from a nurse regarding multiple unspecified patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were unknown. On unknown dates, the patients were vaccinated with doses of improperly stored LIQUID PEDVAXHIB (lot # M027884, expiration date 19-APR-2019) (dose and route unknown) for prophylaxis (incorrect product storage). Concomitant therapies included sterile diluent (manufacturer unknown). The nurse confirmed that sterile diluent (manufacturer unknown) was properly stored. No adverse effects were reported. The temperature excursion was between 47 degrees Fahrenheit (F) to 77.4 degrees F (66.4 degrees F) for a time frame of 3 hours and 22 minutes. There was no previous temperature excursion. This report was because of data logger. This is one of several reports from the same reporter (1708USA002361, 1708USA002362 and 1708USA002363).; Sender's Comments:  US-009507513-1708USA002362: US-009507513-1708USA002363:
Information has been received from a registered nurse referring to a patient of unknown age and gender. Information about concomitant therapy, concurrent condition, drug reactions/allergies and medical history was not provided. On 20-JAN-2017 the patient was vaccinated with an expired dose of ZOSTAVAX (lot # L04044 with expiration date 15-JAN-2017, subcutaneous, strength and dose unknown) for prophylaxis. No side effect was reported. Additional information has been requested.